Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: SGE1

Please read section 7, p9, including comment.

http://209.85.165.104/search?q=cache:rEFEMijr-LMJ:www.txed.uscourts.gov/Rules/GeneralOrders/1999/go99-02.pdf+http://www.txed.uscourts.gov/Rules/GeneralOrders/1999/go99-02.pdf&hl=en&ct=clnk&cd=1

 

As to the S.C. case, Intel and AMD have licensed the MMP Portfolio as well as "system-level" producers.

http://www.alliacense.com/Licensing_Program.aspx

 

The argument therefore is about double-charging for the same licensed product, "Why should we, as system-level producers, have to pay for Intel/AMD chips that have already been licensed?"

The counter is, "The manufacturers were only licensed to make/sell the products, free of per unit royalties. The royalty premium therefore rests with the system-level producer. There is no double, or any other multiple, charging. "

For the S.C. to find for Quanta, it could necessitate renegotiation of the original licenses so that the manufacturers had to pay a per unit cost over and above that already paid for the license. This would lead to problems of past production, current contracts etc.

 

 

Be well

Share
New Message
Please login to post a reply